Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (FRA:FDY)

Germany flag Germany · Delayed Price · Currency is EUR
0.3340
-0.0260 (-7.22%)
At close: Feb 20, 2026
Market Cap867.06M +10.8%
Revenue (ttm)85.20M +2.9%
Net Income-7.50M
EPS-0.01
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume169
Open0.3340
Previous Close0.3600
Day's Range0.3340 - 0.3340
52-Week Range0.3040 - 0.3660
Betan/a
RSI50.02
Earnings DateMar 31, 2026

About FRA:FDY

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and H... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1996
Employees 923
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol FDY
Full Company Profile

Financial Performance

In 2024, FRA:FDY's revenue was 709.40 million, a decrease of -16.61% compared to the previous year's 850.73 million. Earnings were 39.73 million, a decrease of -63.42%.

Financial numbers in CNY Financial Statements